<code id='19C00305CB'></code><style id='19C00305CB'></style>
    • <acronym id='19C00305CB'></acronym>
      <center id='19C00305CB'><center id='19C00305CB'><tfoot id='19C00305CB'></tfoot></center><abbr id='19C00305CB'><dir id='19C00305CB'><tfoot id='19C00305CB'></tfoot><noframes id='19C00305CB'>

    • <optgroup id='19C00305CB'><strike id='19C00305CB'><sup id='19C00305CB'></sup></strike><code id='19C00305CB'></code></optgroup>
        1. <b id='19C00305CB'><label id='19C00305CB'><select id='19C00305CB'><dt id='19C00305CB'><span id='19C00305CB'></span></dt></select></label></b><u id='19C00305CB'></u>
          <i id='19C00305CB'><strike id='19C00305CB'><tt id='19C00305CB'><pre id='19C00305CB'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:73354
          A phone screen displays the webpage of Medicare.gov — coverage from STAT
          Adobe

          Over the past few weeks, Medicare Advantage insurers demanded that the Biden administration give them higher payment rates for next year. The government’s data on how much people were using health care didn’t match their own data, insurers and lobbyists griped — and therefore they wouldn’t be paid enough to cover those costs.

          But the federal government was not persuaded by the industry’s data or lobbying push. The Biden administration and its Medicare agency decided to stick with their proposals from January on Monday, dealing a blow to an insurance industry that has come to rely on Medicare Advantage for a steady stream of profits.

          advertisement

          The result: In 2025, right after a new president is elected, Medicare Advantage insurers will have to absorb a slight decrease of 0.2% to the baseline payment rates that insurers receive from the government for enrolling older adults and people with disabilities. The stock prices of the largest Medicare Advantage insurers — UnitedHealth, Humana, CVS Health, and Elevance Health — all fell by at least 4% in after-hours trading.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          The SUPPORT Act is critical to fighting the opioid crisis
          The SUPPORT Act is critical to fighting the opioid crisis

          AdobeFewpublichealthchallengeshavebeenmoredauntingandpersistentthantheopioidcrisis,whichstartedbecau

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Abbott's new stent may help patients with peripheral artery disease

          CardiovasculardoctorsareoptimisticaboutAbbott’snewbelow-kneestentthatdisappearsintothebloodvessel’sw